UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 

Date of Report
October 12, 2007
 

Nanobac Pharmaceuticals, Incorporated
(Exact name of registrant as specified in its charter)

Florida
(State or Other Jurisdiction of Incorporation)
0-24696
(Commission File Number)
59-3248917
(I.R.S. Employer Identification Number)

4730 N Habana Ave Suite 205 Tampa FL 33614
(Address of Principal Executive Office) (Zip Code)

(813) 264-2241
(Registrant’s telephone number, including area code)

 
 
 

Item 4.01 Changes in Registrant's Certifying Accountant.

(a)       New independent accountants

On October 11, 2007, the Company engaged Rotenberg, Meril, Solomon, Bertiger and Guttilla, P.C. as its new principal independent accountant. The engagement was approved by the Board of Directors on October 10, 2007.
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
 
Nanobac Pharmaceuticals Incorporated.
           (Registrant)
 
  		 
  		 
 
Date: October 12, 2007  By:   /s/ John D. Stanton 
 
John D. Stanton, Chief Executive Officer
   
 
 
2
 
 
Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Nanobac Pharmaceuticals (CE).
Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Nanobac Pharmaceuticals (CE).